148 related articles for article (PubMed ID: 38688620)
1. Risk Factors for Thrombocytopenia Induced by Capecitabine Plus Oxaliplatin Therapy in Patients With Colorectal Cancer.
Kato N; Nakai T; Kodama S; Koyama S; Nakane S; Wada Y; Oda H; Katayama H; Mase H; Miyagawa Y; Miyazaki M; Yamada S; Yamada K
In Vivo; 2024; 38(3):1243-1252. PubMed ID: 38688620
[TBL] [Abstract][Full Text] [Related]
2. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
3. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
Wong GG; Ha V; Chu MP; Dersch-Mills D; Ghosh S; Chambers CR; Sawyer MB
Clin Colorectal Cancer; 2019 Mar; 18(1):72-79. PubMed ID: 30551953
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
5. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
[TBL] [Abstract][Full Text] [Related]
6. Spleen Volume as a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy.
Miyata T; Takamura H; Kin R; Nishiki H; Hashimoto A; Fujii Y; Miura S; Fujita J; Kaida D; Tomita Y; Nakamura N; Fujita H; Kinami S; Ueda N; Kosaka T
Anticancer Res; 2020 Jun; 40(6):3361-3370. PubMed ID: 32487632
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
Boku N; Ryu MH; Kato K; Chung HC; Minashi K; Lee KW; Cho H; Kang WK; Komatsu Y; Tsuda M; Yamaguchi K; Hara H; Fumita S; Azuma M; Chen LT; Kang YK
Ann Oncol; 2019 Feb; 30(2):250-258. PubMed ID: 30566590
[TBL] [Abstract][Full Text] [Related]
8. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
9. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).
Nakayama G; Ishigure K; Yokoyama H; Uehara K; Kojima H; Ishiyama A; Hayashi N; Takano N; Hattori N; Kobayashi D; Tanaka C; Hayashi M; Kanda M; Yamada S; Sugimoto H; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
BMC Cancer; 2017 Apr; 17(1):243. PubMed ID: 28376737
[TBL] [Abstract][Full Text] [Related]
10. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.
Matsumoto N; Kubota Y; Ishida H; Sekido M; Ohkuma R; Ishiguro T; Hirasawa Y; Ariizumi H; Tsunoda T; Ikusue T; Kobayashi K; Hisamatsu A; Toshima H; Shimada K; Fujita KI
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1119-1128. PubMed ID: 32458030
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic efficacy of ninjin'yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2).
Motoo Y; Tomita Y; Fujita H
Int J Clin Oncol; 2020 Jun; 25(6):1123-1129. PubMed ID: 32232692
[TBL] [Abstract][Full Text] [Related]
13. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
[TBL] [Abstract][Full Text] [Related]
14. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Kim ST; Hong YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Lee JW; Jo SJ; Park YS
BMC Cancer; 2014 Nov; 14():883. PubMed ID: 25424120
[TBL] [Abstract][Full Text] [Related]
15. Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection.
Xu JL; Tang CW; Feng WM; Bao Y; Chai ZZ
Med Sci Monit; 2019 Jun; 25():4831-4836. PubMed ID: 31254462
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin‑induced changes in splenic volume and liver fibrosis indices: retrospective analyses of colon cancer patients receiving adjuvant chemotherapy.
Bir Yücel K; Kilic ACK; Sütcüoglu O; Yazıcı O; Kilic K; Savaş G; Uner A; Günel N; Özet A; Özdemir N
J Chemother; 2024 May; 36(3):249-257. PubMed ID: 37578138
[TBL] [Abstract][Full Text] [Related]
17. [The present status of CapeOX as adjuvant chemotherapy for colorectal cancer].
Ishii K; Kanamoto A; Miyanaga S; Noto M; Takeda T; Tani T; Yagi M
Gan To Kagaku Ryoho; 2015 Mar; 42(3):319-22. PubMed ID: 25812500
[TBL] [Abstract][Full Text] [Related]
18. An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
Brady J; Corrie P; Chau I; Digumarti R; Adams LM; Botbyl J; Laubscher KH; Midgley RS; Mallath M
Invest New Drugs; 2013 Oct; 31(5):1228-35. PubMed ID: 23456563
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).
Terazawa T; Matsuyama J; Goto M; Kawabata R; Endo S; Imano M; Fujita S; Akamaru Y; Taniguchi H; Tatsumi M; Lee SW; Kurisu Y; Kawakami H; Kurokawa Y; Shimokawa T; Sakai D; Kato T; Fujitani K; Satoh T
Oncologist; 2020 Feb; 25(2):119-e208. PubMed ID: 32043772
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy.
Yokokawa T; Kawakami K; Mae Y; Sugita K; Watanabe H; Suzuki K; Suenaga M; Mizunuma N; Yamaguchi T; Hama T
Ann Pharmacother; 2015 Oct; 49(10):1120-4. PubMed ID: 26160973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]